Lead the conversation at the 2nd Translational Digital Pathology & AI Summit, where biopharma leaders driving digital pathology unite for exclusive, high impact networking discussions in intimate, deep-dive sessions.
Showcase your technology and expertise to the key decision-makers shaping the future of digital pathology. Demonstrate how your platform can support them by streamlining operational workflows, revealing novel insights, and uncovering more precise biomarkers, opening the door to your next major partnership.
At a time where the field demands alignment, position your organization as a leader easing implementation, driving standardization, and boosting the adoption of digital pathology.
Why Partner?
 |
Connect directly with senior biopharma decision-makers actively seeking innovative AI, image analysis, and digital pathology solutions to advance their R&D and clinical programs |
 |
Position your technology as a critical enabler for improving diagnostic accuracy, accelerating drug development, and unlocking new biomarker and CDx opportunities |
 |
Showcase your expertise and thought leadership alongside industry pioneers, strengthening your brand and driving meaningful collaborations across biopharma and diagnostics |
Biopharma Companies Are Looking to Partner With
Official Event Partner
AIRA Matrix provides AI solutions for Clinical and Life Sciences applications, improving efficiency, diagnostic accuracy, and turnaround times in pathology workflows, with diagnostic, prognostic, and predictive cancer care tools that support disease stratification and personalized treatment protocols to enhance outcomes.
Want to Learn More About Partnering?
Contact Thomas Walsh, Partnerships Director at: sponsor@hansonwade.com
Who Will You Meet?
Connect with Directors, Heads, and Vice Presidents of Pathology, Translational Research, Image Analysis, Precision Medicine, Data Science, and more, showcasing your organization's solutions to support them in overcoming the key challenges they're currently facing.
These include the lack of versatility and standardization in protocols and building digitally enabled IT infrastructures that fully support digital pathology across the full workflow for better patient outcomes.
